NMPA Approves Marketing Update for Baiyunshan's Drug Products

The National Medical Products Administration has approved a supplementary medication application for Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Company. The permission relates to a modification in the topic of the drug marketing authorisation for their product, Pseudoephedrine Granules and Compound Paracetamol. The company's product portfolio is taking a significant stride forward with this regulatory milestone.